Emerging role of NRF2 in ROS-mediated tumor chemoresistance.
Chemoresistance
NRF2
Reactive oxygen species
Journal
Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie
ISSN: 1950-6007
Titre abrégé: Biomed Pharmacother
Pays: France
ID NLM: 8213295
Informations de publication
Date de publication:
Nov 2020
Nov 2020
Historique:
received:
04
07
2020
revised:
16
08
2020
accepted:
20
08
2020
pubmed:
29
8
2020
medline:
20
2
2021
entrez:
29
8
2020
Statut:
ppublish
Résumé
Chemoresistance is a central cause for the tumor management failure. Cancer cells disrupt the redox homeostasis through reactive oxygen species (ROS) regulatory mechanisms, leading to tumor progression and chemoresistance. The transcription factor nuclear factor erythroid 2-related factor 2 (NRF2) is a master regulator of neutralizing cellular ROS and restoring redox balance. Understanding the role of NRF2 in ROS-mediated chemoresistance can be helpful in the development of chemotherapy strategies with better efficiency. In this review, we sum up the roles of ROS in the development of chemoresistance to classical chemotherapy agents including cisplatin, 5-fluorouracil, gemcitabine, oxaliplatin, paclitaxel, and doxorubicin, and how to overcome ROS-mediated tumor chemoresistance by targeting NRF2. Finally, we propose that targeting NRF2 might be a promising strategy to resist ROS-driven chemoresistance and acquire better efficacy in cancer treatment.
Identifiants
pubmed: 32858502
pii: S0753-3322(20)30869-6
doi: 10.1016/j.biopha.2020.110676
pii:
doi:
Substances chimiques
Antineoplastic Agents
0
NF-E2-Related Factor 2
0
NFE2L2 protein, human
0
Reactive Oxygen Species
0
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
110676Informations de copyright
Copyright © 2020 The Authors. Published by Elsevier Masson SAS.. All rights reserved.